Table I.
Experimental design
| Piglet age (wk) | ||||||
|---|---|---|---|---|---|---|
|
|
||||||
| 0 | 1 Early |
2 | 3 | 4 Late |
5 PCV2 challengeb |
|
| Treatment and groupa | KLHc (n = 12) | KLHc (n = 10) | KLH (n = 12) | |||
| VACd (n = 11) | VACd (n = 11) | VAC (n = 11) Never-VAC (n = 11) |
||||
a
All piglets were monitored and sampled twice weekly. Quantitative PCV2-PCR, ELISA for anti-KLH antibodies, and virus neutralization assay (VNA) for PCV2-neutralizing antibodies were carried out on most serum and saliva samples. All statistical analysis were conducted using JMP 12 software (SAS Institute), applying a critical alpha.
b
105 TCID50 PCV2 (intranasal).
c
~1.1 mg KLH in adjuvant per piglet (intramuscular).
d
A single dose of Circumvent PCV was used.